The invention provides (1) processes for making substantially-pure (-) huperzine A and substantially-pure (-) huperzine A derivatives; (2) compositions useful in making substantially-pure (-) huperzine A and substantially-pure (-) huperzine A derivatives; and (3) methods of treating or preventing neurological disorders using substantially-pure (-) huperzine A and substantially-pure (-) huperzine A derivatives.
该发明提供了三个方面:(1) 制备几乎纯的(-)华佩嗪A和几乎纯的(-)华佩嗪A衍
生物的过程;(2) 用于制备几乎纯的(-)华佩嗪A和几乎纯的(-)华佩嗪A衍
生物的组合物;以及(3) 使用几乎纯的(-)华佩嗪A和几乎纯的(-)华佩嗪A衍
生物治疗或预防神经系统疾病的方法。